|Application ||WB, E|
|Other Accession||NP_003857, 156104895|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||Predicted: 102 kDa |
Observed: 100 kDa
|Application Notes||INPP4B antibody can be used for detection of INPP4B by Western blot at 1 - 2 µg/ml.|
|Target/Specificity||INPP4B; INPP4B antibody is human, mouse and rat reactive. At least two isoforms of INPP4B are known to exist; this antibody only detects the longer isoform. INPP4B antibody is predicted to not cross-react with INPP4A.|
|Reconstitution & Storage||INPP4B antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||INPP4B Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Inositol polyphosphate 4-phosphatase type II (INPP4B) is one of the enzymes involved in phosphatidylinositol signaling pathways. It removes the phosphate group at position 4 of the inositol ring from inositol 3,4-bisphosphate (1). INPP4B can function as a tumor suppressor by inhibiting PI3K signaling. In human epithelial cells, knockdown of INPP4B expression resulted in enhanced Akt activation, anchorage-independent growth, and enhanced overall motility (2). It is thought INPP4B may also have oncogenic functions as INPP4B-dependent PI3K signaling is mediated by SGK3 in breast cancer cells and expression of INPP4B leads to enhanced SGK3 activation and suppression of AKT phosphorylation (3).
Norris FA, Auethavekiat V, and Majerus PW. The isolation and characterization of cDNA encoding human and rat brain inositol polyphosphate 4-phosphase. J. Biol. Chem. 1995; 270:16128-33.
Gewinner C, Wang ZC, Richardson A, et al. Evidence that inositol polyphosphate 4-phosphase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009; 16:115-25.
Gasser JA, Inuzuka H, Lau AW, et al. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol. Cell 2014; 56:595-607.
If you have any additional inquiries please email technical services at email@example.com.